23andMe Holding Co. ME

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
35/100
Developing

Ranked against 61 peers in Diagnostics & Research

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.76). Low volatility confirms durable consumable pricing.
  • Durable Revenue Growth Revenue growth trend is strong (score 0.85). Durable top-line expansion confirms the razor-and-blade flywheel is working.

Key risks

  • Weak FCF Generation FCF margin quality lags peers (score 0.23). Below-peer FCF conversion is a MedTech quality warning.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
56
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where ME ranks in Diagnostics & Research

23andMe Holding Co. ranks #45 of 62 scored companies in Diagnostics & Research by moat score — the top 73%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

# Company Moat score Rating
41 Opko Health, Inc. OPK 42/100 Developing
42 Fulgent Genetics, Inc. FLGT 42/100 Developing
43 Mainz Biomed N.V. MYNZ 37/100 Developing
44 Inotiv, Inc. NOTV 37/100 Developing
45 23andMe Holding Co. ME 35/100 Developing
46 XWELL, Inc. XWEL 34/100 Developing
47 GRAIL, Inc. GRAL 32/100 Developing
48 Personalis, Inc. PSNL 30/100 Developing
49 bioAffinity Technologies, Inc. BIAF 29/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How ME scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 56 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 23 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 20 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 14 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 35 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 53 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding ME's moat

What is 23andMe Holding Co.'s moat score?

23andMe Holding Co. (ME) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #45 of 62 scored companies in Diagnostics & Research, the top 73%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (56/100) and its weakest is Commercial Execution (14/100).

How does 23andMe Holding Co. compare with other Diagnostics & Research companies?

23andMe Holding Co. ranks #45 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Inotiv, Inc. (NOTV) at 37 just above it and XWELL, Inc. (XWEL) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is 23andMe Holding Co. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for 23andMe Holding Co.?

The Medical Devices & Diagnostics template measures 6 defenses, and ME scores: Pricing Power & Consumable Moat (56), R&D Pipeline & Capital Returns (23), FCF Quality & Cash Conversion (20), Commercial Execution (14), Capital Structure & Resilience (35), Growth Durability (53). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000